Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-04

AUTHORS

James J. Harding, Todd M. Bauer, Daniel S. W. Tan, Philippe L. Bedard, Jordi Rodon, Toshihiko Doi, Christian Schnell, Varsha Iyer, Fabienne Baffert, Rajkumar Radhakrishnan, Claire Fabre, Dejan Juric

ABSTRACT

Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determine the maximum tolerated dose (MTD), safety, PK, and efficacy of CLR457. Successive cohorts of patients with advanced solid tumors with PI3K pathway activation received increasing CLR457 doses according to a Bayesian escalation model based on the rate of dose limiting toxicity (DLT) in the first 28-day cycle. Results CLR457 inhibited p110α, p110β, p110δ and p110γ isoforms with an IC50 of 89 ± 29 nM, 56 ± 35 nM, 39 ± 10 nM and 230 ± 31 nM, respectively. CLR457 exhibited dose-dependent antitumor activity and interfered with glucose homeostasis in PI3K-mutant tumor xenografts. 31 patients received doses ranging from 5 to 100 mg. DLTs included grade 3 hyperglycemia and rash (3). In the 100 mg cohort (n = 11), 3 (27.3%) patients had DLTs and all patients (100%) experienced ≥ grade 3 toxicity with rash (45.5%) as the most common event. The MTD was not determined. For the entire study population, stomatitis (45.2%), diarrhea (38.7%), rash (35.5%) were the most common any grade toxicities-51.6% patients experienced ≥ Grade 3 toxicity. CLR457 was rapidly absorbed with limited accumulation and linear PK. PK modeling indicated that pharmacologically active concentrations were achieved at the highest dose tested (100 mg), though no objective responses were observed. Conclusion CLR457 clinical development was terminated due to poor tolerability and limited antitumor activity. These results emphasize the difficulty of achieving a wide therapeutic index when targeting all class I PI3K-isoforms. More... »

PAGES

271-281

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-018-0627-4

DOI

http://dx.doi.org/10.1007/s10637-018-0627-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1105980218

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30073466


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harding", 
        "givenName": "James J.", 
        "id": "sg:person.01154466504.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154466504.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Tennessee Oncology", 
          "id": "https://www.grid.ac/institutes/grid.492963.3", 
          "name": [
            "Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bauer", 
        "givenName": "Todd M.", 
        "id": "sg:person.01343430002.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Centre Singapore", 
          "id": "https://www.grid.ac/institutes/grid.410724.4", 
          "name": [
            "National Cancer Centre, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tan", 
        "givenName": "Daniel S. W.", 
        "id": "sg:person.010675577122.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010675577122.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Princess Margaret Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.415224.4", 
          "name": [
            "Princess Margaret Cancer Centre, Toronto, ON, Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bedard", 
        "givenName": "Philippe L.", 
        "id": "sg:person.0734035230.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734035230.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital Universitari Vall d'Hebron", 
          "id": "https://www.grid.ac/institutes/grid.411083.f", 
          "name": [
            "Hospital Vall D\u2019Hebron, Catalunia, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodon", 
        "givenName": "Jordi", 
        "id": "sg:person.0640557257.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640557257.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National Cancer Centre", 
          "id": "https://www.grid.ac/institutes/grid.272242.3", 
          "name": [
            "National Cancer Center East, Kashiwa, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Doi", 
        "givenName": "Toshihiko", 
        "id": "sg:person.01143000213.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143000213.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schnell", 
        "givenName": "Christian", 
        "id": "sg:person.01332122227.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332122227.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Agios Pharmaceuticals (United States)", 
          "id": "https://www.grid.ac/institutes/grid.427815.d", 
          "name": [
            "Agios Pharmaceuticals, Inc., Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iyer", 
        "givenName": "Varsha", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baffert", 
        "givenName": "Fabienne", 
        "id": "sg:person.0642560151.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642560151.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Radhakrishnan", 
        "givenName": "Rajkumar", 
        "id": "sg:person.016406144420.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016406144420.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fabre", 
        "givenName": "Claire", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Massachusetts General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.32224.35", 
          "name": [
            "Massachusetts General Hospital, 55 Fruit St, 02114, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Juric", 
        "givenName": "Dejan", 
        "id": "sg:person.0776511143.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776511143.21"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/s0140-6736(15)00817-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009071749"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834011422556", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011306841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1758834011422556", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011306841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04694", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011965244", 
          "https://doi.org/10.1038/nature04694"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04694", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011965244", 
          "https://doi.org/10.1038/nature04694"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature04694", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011965244", 
          "https://doi.org/10.1038/nature04694"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2006.03.035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012987973"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-11-0474", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019475476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1753", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026259547", 
          "https://doi.org/10.1038/nrc1753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1753", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026259547", 
          "https://doi.org/10.1038/nrc1753"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(16)00106-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029284680"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1109653", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029978324"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2013.10", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031948211", 
          "https://doi.org/10.1038/nrclinonc.2013.10"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-05-2620", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032388482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2008.245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038283584", 
          "https://doi.org/10.1038/onc.2008.245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1043-2760(02)00662-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040323482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1043-2760(02)00662-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040323482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cmdc.201600148", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040414497"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-14-0947", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040596133"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/pst.484", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040983889"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2013.74", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043052640", 
          "https://doi.org/10.1038/onc.2013.74"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2013.74", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043052640", 
          "https://doi.org/10.1038/onc.2013.74"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043430958", 
          "https://doi.org/10.1038/nrd2926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd2926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043430958", 
          "https://doi.org/10.1038/nrd2926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.296.5573.1655", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043624396"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1819", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044083124", 
          "https://doi.org/10.1038/nrc1819"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1819", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044083124", 
          "https://doi.org/10.1038/nrc1819"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(08)61039-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045744105"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.3230", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049460199"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm800295d", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055955582"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/jm800295d", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1055955582"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1021/ml200156t", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056211208"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1538-7445.sabcs15-p1-14-01", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063274992"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.73.0143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085386616"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30376-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085716832"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2017.07.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091143814"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-04", 
    "datePublishedReg": "2019-04-01", 
    "description": "Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determine the maximum tolerated dose (MTD), safety, PK, and efficacy of CLR457. Successive cohorts of patients with advanced solid tumors with PI3K pathway activation received increasing CLR457 doses according to a Bayesian escalation model based on the rate of dose limiting toxicity (DLT) in the first 28-day\u00a0cycle. Results CLR457 inhibited p110\u03b1, p110\u03b2, p110\u03b4 and p110\u03b3 isoforms with an IC50 of 89\u2009\u00b1\u200929\u00a0nM, 56\u2009\u00b1\u200935\u00a0nM, 39\u2009\u00b1\u200910\u00a0nM and 230\u2009\u00b1\u200931\u00a0nM, respectively. CLR457 exhibited dose-dependent antitumor activity and interfered with glucose homeostasis in PI3K-mutant tumor xenografts. 31 patients received doses ranging from 5 to 100\u00a0mg. DLTs included grade 3 hyperglycemia and rash (3). In the 100\u00a0mg cohort (n\u2009=\u200911), 3 (27.3%) patients had DLTs and all patients (100%) experienced \u2265 grade 3 toxicity with rash (45.5%) as the most common event. The MTD was not determined. For the entire study population, stomatitis (45.2%), diarrhea (38.7%), rash (35.5%) were the most common any grade toxicities-51.6% patients experienced \u2265 Grade 3 toxicity. CLR457 was rapidly absorbed with limited accumulation and linear PK. PK modeling indicated that pharmacologically active concentrations were achieved at the highest dose tested (100\u00a0mg), though no objective responses were observed. Conclusion CLR457 clinical development was terminated due to poor tolerability and limited antitumor activity. These results emphasize the difficulty of achieving a wide therapeutic index when targeting all class I PI3K-isoforms.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-018-0627-4", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "37"
      }
    ], 
    "name": "Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor", 
    "pagination": "271-281", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d285fe9b5bd522b66032d7bbea69699328433b16e5fbd76292285765117053be"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30073466"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-018-0627-4"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1105980218"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-018-0627-4", 
      "https://app.dimensions.ai/details/publication/pub.1105980218"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000369_0000000369/records_68944_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-018-0627-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0627-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0627-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0627-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-018-0627-4'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      21 PREDICATES      57 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-018-0627-4 schema:about anzsrc-for:11
2 anzsrc-for:1115
3 schema:author Ncda6b6343ad04f1da86bee8c284ec4c0
4 schema:citation sg:pub.10.1038/nature04694
5 sg:pub.10.1038/nrc1753
6 sg:pub.10.1038/nrc1819
7 sg:pub.10.1038/nrclinonc.2013.10
8 sg:pub.10.1038/nrd2926
9 sg:pub.10.1038/onc.2008.245
10 sg:pub.10.1038/onc.2013.74
11 https://doi.org/10.1002/cmdc.201600148
12 https://doi.org/10.1002/pst.484
13 https://doi.org/10.1002/sim.3230
14 https://doi.org/10.1016/j.cell.2006.03.035
15 https://doi.org/10.1016/j.cell.2017.07.029
16 https://doi.org/10.1016/j.ejca.2008.10.026
17 https://doi.org/10.1016/s0140-6736(08)61039-9
18 https://doi.org/10.1016/s0140-6736(15)00817-x
19 https://doi.org/10.1016/s1043-2760(02)00662-8
20 https://doi.org/10.1016/s1470-2045(16)00106-6
21 https://doi.org/10.1016/s1470-2045(17)30376-5
22 https://doi.org/10.1021/jm800295d
23 https://doi.org/10.1021/ml200156t
24 https://doi.org/10.1056/nejmoa1109653
25 https://doi.org/10.1126/science.296.5573.1655
26 https://doi.org/10.1158/0008-5472.can-05-2620
27 https://doi.org/10.1158/1078-0432.ccr-14-0947
28 https://doi.org/10.1158/1535-7163.mct-11-0474
29 https://doi.org/10.1158/1538-7445.sabcs15-p1-14-01
30 https://doi.org/10.1177/1758834011422556
31 https://doi.org/10.1200/jco.2017.73.0143
32 schema:datePublished 2019-04
33 schema:datePublishedReg 2019-04-01
34 schema:description Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determine the maximum tolerated dose (MTD), safety, PK, and efficacy of CLR457. Successive cohorts of patients with advanced solid tumors with PI3K pathway activation received increasing CLR457 doses according to a Bayesian escalation model based on the rate of dose limiting toxicity (DLT) in the first 28-day cycle. Results CLR457 inhibited p110α, p110β, p110δ and p110γ isoforms with an IC<sub>50</sub> of 89 ± 29 nM, 56 ± 35 nM, 39 ± 10 nM and 230 ± 31 nM, respectively. CLR457 exhibited dose-dependent antitumor activity and interfered with glucose homeostasis in PI3K-mutant tumor xenografts. 31 patients received doses ranging from 5 to 100 mg. DLTs included grade 3 hyperglycemia and rash (3). In the 100 mg cohort (n = 11), 3 (27.3%) patients had DLTs and all patients (100%) experienced ≥ grade 3 toxicity with rash (45.5%) as the most common event. The MTD was not determined. For the entire study population, stomatitis (45.2%), diarrhea (38.7%), rash (35.5%) were the most common any grade toxicities-51.6% patients experienced ≥ Grade 3 toxicity. CLR457 was rapidly absorbed with limited accumulation and linear PK. PK modeling indicated that pharmacologically active concentrations were achieved at the highest dose tested (100 mg), though no objective responses were observed. Conclusion CLR457 clinical development was terminated due to poor tolerability and limited antitumor activity. These results emphasize the difficulty of achieving a wide therapeutic index when targeting all class I PI3K-isoforms.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N0da54e3a18a54e26bbc2d8dc7a5d0f75
39 N3e582dbad04e454d901092eddd9f7cfb
40 sg:journal.1094201
41 schema:name Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor
42 schema:pagination 271-281
43 schema:productId N101c8f6e8038414a98d1a0fef89e60c5
44 N76119649ffde421a990f7e9befa3a002
45 N81780cf71b494209ae72684e8af31438
46 Nb1e6b09ec4e546e0899c5071eeec22e3
47 Nee686132180c4108b6adf08fdc616d70
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105980218
49 https://doi.org/10.1007/s10637-018-0627-4
50 schema:sdDatePublished 2019-04-11T13:23
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher Nc16c5702e2bc465bb1253d59934b8d20
53 schema:url https://link.springer.com/10.1007%2Fs10637-018-0627-4
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N0a647f766e914a8e8d714ee0a9946f82 rdf:first N81ca55fb3724491289d40269a082cd45
58 rdf:rest Nb82c630f04794226a50471c64e37097b
59 N0da54e3a18a54e26bbc2d8dc7a5d0f75 schema:issueNumber 2
60 rdf:type schema:PublicationIssue
61 N0fff98ecd07743fd8d8ec1e97735ab45 rdf:first Na1fa7e81fb6945c0a176ca984785a0e9
62 rdf:rest N8e284c4ac69d4a6a872d2d15db60cc32
63 N101c8f6e8038414a98d1a0fef89e60c5 schema:name nlm_unique_id
64 schema:value 8309330
65 rdf:type schema:PropertyValue
66 N3e582dbad04e454d901092eddd9f7cfb schema:volumeNumber 37
67 rdf:type schema:PublicationVolume
68 N47c789201cf54d5bb8e01ccce00267e8 rdf:first sg:person.010675577122.22
69 rdf:rest N4d0308726c7b4d07af172965ed91c6b6
70 N4d0308726c7b4d07af172965ed91c6b6 rdf:first sg:person.0734035230.66
71 rdf:rest N57b4d647923947a78afaca658945ce94
72 N52d50de4aa4d4192a93ed815d29288cd rdf:first sg:person.016406144420.98
73 rdf:rest N0fff98ecd07743fd8d8ec1e97735ab45
74 N57b4d647923947a78afaca658945ce94 rdf:first sg:person.0640557257.82
75 rdf:rest Nd6558bdd75d34af2a1a14c4e93eb5ffd
76 N57f68a000d094d8c8db3471650dcb7e9 rdf:first sg:person.01332122227.21
77 rdf:rest N0a647f766e914a8e8d714ee0a9946f82
78 N76119649ffde421a990f7e9befa3a002 schema:name dimensions_id
79 schema:value pub.1105980218
80 rdf:type schema:PropertyValue
81 N81780cf71b494209ae72684e8af31438 schema:name pubmed_id
82 schema:value 30073466
83 rdf:type schema:PropertyValue
84 N81ca55fb3724491289d40269a082cd45 schema:affiliation https://www.grid.ac/institutes/grid.427815.d
85 schema:familyName Iyer
86 schema:givenName Varsha
87 rdf:type schema:Person
88 N8e284c4ac69d4a6a872d2d15db60cc32 rdf:first sg:person.0776511143.21
89 rdf:rest rdf:nil
90 Na1fa7e81fb6945c0a176ca984785a0e9 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
91 schema:familyName Fabre
92 schema:givenName Claire
93 rdf:type schema:Person
94 Nb1e6b09ec4e546e0899c5071eeec22e3 schema:name readcube_id
95 schema:value d285fe9b5bd522b66032d7bbea69699328433b16e5fbd76292285765117053be
96 rdf:type schema:PropertyValue
97 Nb82c630f04794226a50471c64e37097b rdf:first sg:person.0642560151.68
98 rdf:rest N52d50de4aa4d4192a93ed815d29288cd
99 Nc16c5702e2bc465bb1253d59934b8d20 schema:name Springer Nature - SN SciGraph project
100 rdf:type schema:Organization
101 Ncda6b6343ad04f1da86bee8c284ec4c0 rdf:first sg:person.01154466504.00
102 rdf:rest Nf4ae21af81054799871bc8112f1d2edd
103 Nd6558bdd75d34af2a1a14c4e93eb5ffd rdf:first sg:person.01143000213.41
104 rdf:rest N57f68a000d094d8c8db3471650dcb7e9
105 Nee686132180c4108b6adf08fdc616d70 schema:name doi
106 schema:value 10.1007/s10637-018-0627-4
107 rdf:type schema:PropertyValue
108 Nf4ae21af81054799871bc8112f1d2edd rdf:first sg:person.01343430002.75
109 rdf:rest N47c789201cf54d5bb8e01ccce00267e8
110 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
111 schema:name Medical and Health Sciences
112 rdf:type schema:DefinedTerm
113 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
114 schema:name Pharmacology and Pharmaceutical Sciences
115 rdf:type schema:DefinedTerm
116 sg:journal.1094201 schema:issn 0167-6997
117 1573-0646
118 schema:name Investigational New Drugs
119 rdf:type schema:Periodical
120 sg:person.010675577122.22 schema:affiliation https://www.grid.ac/institutes/grid.410724.4
121 schema:familyName Tan
122 schema:givenName Daniel S. W.
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010675577122.22
124 rdf:type schema:Person
125 sg:person.01143000213.41 schema:affiliation https://www.grid.ac/institutes/grid.272242.3
126 schema:familyName Doi
127 schema:givenName Toshihiko
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01143000213.41
129 rdf:type schema:Person
130 sg:person.01154466504.00 schema:affiliation https://www.grid.ac/institutes/grid.51462.34
131 schema:familyName Harding
132 schema:givenName James J.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154466504.00
134 rdf:type schema:Person
135 sg:person.01332122227.21 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
136 schema:familyName Schnell
137 schema:givenName Christian
138 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332122227.21
139 rdf:type schema:Person
140 sg:person.01343430002.75 schema:affiliation https://www.grid.ac/institutes/grid.492963.3
141 schema:familyName Bauer
142 schema:givenName Todd M.
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343430002.75
144 rdf:type schema:Person
145 sg:person.016406144420.98 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
146 schema:familyName Radhakrishnan
147 schema:givenName Rajkumar
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016406144420.98
149 rdf:type schema:Person
150 sg:person.0640557257.82 schema:affiliation https://www.grid.ac/institutes/grid.411083.f
151 schema:familyName Rodon
152 schema:givenName Jordi
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0640557257.82
154 rdf:type schema:Person
155 sg:person.0642560151.68 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
156 schema:familyName Baffert
157 schema:givenName Fabienne
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0642560151.68
159 rdf:type schema:Person
160 sg:person.0734035230.66 schema:affiliation https://www.grid.ac/institutes/grid.415224.4
161 schema:familyName Bedard
162 schema:givenName Philippe L.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734035230.66
164 rdf:type schema:Person
165 sg:person.0776511143.21 schema:affiliation https://www.grid.ac/institutes/grid.32224.35
166 schema:familyName Juric
167 schema:givenName Dejan
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776511143.21
169 rdf:type schema:Person
170 sg:pub.10.1038/nature04694 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011965244
171 https://doi.org/10.1038/nature04694
172 rdf:type schema:CreativeWork
173 sg:pub.10.1038/nrc1753 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026259547
174 https://doi.org/10.1038/nrc1753
175 rdf:type schema:CreativeWork
176 sg:pub.10.1038/nrc1819 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044083124
177 https://doi.org/10.1038/nrc1819
178 rdf:type schema:CreativeWork
179 sg:pub.10.1038/nrclinonc.2013.10 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031948211
180 https://doi.org/10.1038/nrclinonc.2013.10
181 rdf:type schema:CreativeWork
182 sg:pub.10.1038/nrd2926 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043430958
183 https://doi.org/10.1038/nrd2926
184 rdf:type schema:CreativeWork
185 sg:pub.10.1038/onc.2008.245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038283584
186 https://doi.org/10.1038/onc.2008.245
187 rdf:type schema:CreativeWork
188 sg:pub.10.1038/onc.2013.74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043052640
189 https://doi.org/10.1038/onc.2013.74
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1002/cmdc.201600148 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040414497
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1002/pst.484 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040983889
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1002/sim.3230 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049460199
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/j.cell.2006.03.035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012987973
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/j.cell.2017.07.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091143814
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/s0140-6736(08)61039-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045744105
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/s0140-6736(15)00817-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1009071749
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/s1043-2760(02)00662-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040323482
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1016/s1470-2045(16)00106-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029284680
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/s1470-2045(17)30376-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085716832
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1021/jm800295d schema:sameAs https://app.dimensions.ai/details/publication/pub.1055955582
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1021/ml200156t schema:sameAs https://app.dimensions.ai/details/publication/pub.1056211208
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1056/nejmoa1109653 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029978324
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1126/science.296.5573.1655 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043624396
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1158/0008-5472.can-05-2620 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032388482
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1158/1078-0432.ccr-14-0947 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040596133
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1158/1535-7163.mct-11-0474 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019475476
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1158/1538-7445.sabcs15-p1-14-01 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063274992
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1177/1758834011422556 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011306841
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.2017.73.0143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085386616
232 rdf:type schema:CreativeWork
233 https://www.grid.ac/institutes/grid.272242.3 schema:alternateName National Cancer Centre
234 schema:name National Cancer Center East, Kashiwa, Chiba, Japan
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.32224.35 schema:alternateName Massachusetts General Hospital
237 schema:name Massachusetts General Hospital, 55 Fruit St, 02114, Boston, MA, USA
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.410724.4 schema:alternateName National Cancer Centre Singapore
240 schema:name National Cancer Centre, Singapore, Singapore
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.411083.f schema:alternateName Hospital Universitari Vall d'Hebron
243 schema:name Hospital Vall D’Hebron, Catalunia, Barcelona, Spain
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.415224.4 schema:alternateName Princess Margaret Cancer Centre
246 schema:name Princess Margaret Cancer Centre, Toronto, ON, Canada
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
249 schema:name Novartis Pharma AG, Basel, Switzerland
250 rdf:type schema:Organization
251 https://www.grid.ac/institutes/grid.427815.d schema:alternateName Agios Pharmaceuticals (United States)
252 schema:name Agios Pharmaceuticals, Inc., Cambridge, MA, USA
253 rdf:type schema:Organization
254 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
255 schema:name Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India
256 rdf:type schema:Organization
257 https://www.grid.ac/institutes/grid.492963.3 schema:alternateName Tennessee Oncology
258 schema:name Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN, USA
259 rdf:type schema:Organization
260 https://www.grid.ac/institutes/grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center
261 schema:name Memorial Sloan Kettering Cancer Center, New York, NY, USA
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...